FDA warns of possible cancer risk with lorcaserin

FDA warned Tuesday of a possible increased with of cancer with lorcaserin (Belviq, Belviq XR—Eisai). According to the agency, "At this time, the cause of the cancer is uncertain, and we cannot conclude that lorcaserin contributes to the cancer risk.

FDA warned Tuesday of a possible increased with of cancer with lorcaserin (Belviq, Belviq XR—Eisai). According to the agency, "At this time, the cause of the cancer is uncertain, and we cannot conclude that lorcaserin contributes to the cancer risk. However, we wanted to make the public aware of this potential risk." FDA said it would continue to evaluate the results of the clinical trial that indicated the potential risk, and "will communicate our final conclusions and recommendations when we have completed our review." When deciding whether to prescribe or continue patients on lorcaserin, FDA said health care providers should consider whether the benefits of taking the drug are likely to exceed the potential risks. Additionally, patients currently taking lorcaserin should discuss the potential increased risk of cancer with their health care providers.